We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Gene Silencing Protein Found to Be Enzyme Modifier

By Biotechdaily staff writers
Posted on 24 Jan 2003
Researchers have found that the Sir2 protein, known to be required for gene silencing, modifies the enzyme acetyl-CoA synthetase that may be related to the extended lifespan in many organisms resulting when calories are restricted. More...
The finding was reported in the December 20, 2002, issue of Science.

Silencing is a form of transcriptional repression that renders large chromatin domains inaccessible to the transcription machinery. Silenced domains are refractile to recombination, replicate late in S phase and are inaccessible to some but not all molecular probes. In Saccharomyces cerevisiae (budding yeast) silencing occurs at three loci: the cryptic mating type loci, HMR and HML; the telomeres (referred as telomeric position effect, TPE); and at the rDNA locus (called RPE).

SIR2 distinguishes itself from the other SIR genes as it is essential for the three types of silencing and is conserved from bacteria to man. Four paralogs of Sir2p exist in budding yeast, the Hst1-4 proteins, and more than one Sir2 ortholog is found in all other species examined. They are called sirtuins. Recently, numerous studies have demonstrated that Sir2p is an in vitro NAD-dependent deacetylase and that this enzymatic activity appears to correlate with repression at the HM, telomeres, and rDNA loci. However, the physiologic Sir2p substrates have not yet been identified.

Working with a mutated strain of bacteria lacking sirtuins, investigators from Johns Hopkins University (Baltimore, MD, USA; www.jhu.edu) and the University of Wisconsin (Madison, USA; www.wisc.edu) discovered that Sir2 was a crucial modifier of the enzyme acetyl-CoA synthetase, which converts acetate into acetyl-CoA in a two-step process. Acetyl-CoA then can directly fuel the citric acid cycle, the central energy-producing step in cellular respiration.

"This is a completely new target for the sirtuin protein,” explained investigator Dr. Jeff Boeke, professor of molecular biology and genetics at Johns Hopkins' Institute for Basic Biomedical Sciences. "Converting acetate is not the cell's only way of making acetyl-CoA, but when acetate is the major energy source, it is crucial. Now we have to check for this role in other organisms.”




Related Links:
John Hopkins University
University of Wisconsin

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
All-in-One Molecular System
AIO M160
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.